Skip to main content

Pacific Biosciences of California, Inc.

corporate_fare Company Profile

Pacific Biosciences of California, Inc.

PACB·NASDAQ·Industrial Applications And Services·CIK 0001299130

We are a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions. Our products, including our HiFi long-read sequencing technology, help scientists and clinical researchers understand the genome to resolve genetically complex problems. Our technology addresses applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. We aim to create advanced sequencing systems that provide customers with a complete and accurate view of genomes, transcriptomes, and epigenomes. Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations ("CROs"), pharmaceutical companies, and agricultural companies. On January 30, 2026, we completed the sale of certain intellectual property and other assets related to our short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina Cambridge Limited. As consideration, Illumina Cambridge Limited paid us $50.0 million in cash and assumed certain liabilities. We also received a non-exclusive license to certain intellectual property included in the purchased assets. In connection with this sale, 4% of the net proceeds from the purchase price will be paid to the former equity holders of Apton Biosystems, Inc. related to the waiver of all remaining milestone obligations associated with our purchase of Apton in August 2023. This payment is expected in the first quarter of 2026. As a result, we received approximately $48.1 million in net cash proceeds from the asset sale.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 28 items for PACB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 8 rated 8 or above. Recent SEC coverage for PACB spans 424B5, 8-K, 10-Q, DEFA14A.

Recent high-impact activity:

  • PacBio Launches $100M At-The-Market Stock Program Via Allen & Company
  • PacBio Adds GeneDx, TychoBio Deals Alongside Q3 Revenue Growth and CFO Handoff
  • CFO Exits Days After Q3 Loss as PacBio Turnaround Stumbles
  • PacBio Q3 Loss Widens Marginally as CFO Exits; Guidance Narrowed to $155M-$160M
  • PacBio Posts 12-Cent Quarterly Loss as Turnaround Pressure Mounts

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$160M
Net Income
-$546.38M
Diluted EPS
-$1.82
Op. Cash Flow
-$111.21M
Free Cash Flow
-$113.92M
Gross Profit
$45.78M
Operating Income
-$553.86M
Cash & Equivalents
$63.71M
Debt / Equity
0.00×
Net Margin
-341.5%
Shares Outstanding
301.96M sh
Source: 10-K · filed 2026-02-25 · accession 0001299130-26-000034

Short Interest & Short Volume

4.14 days to cover

FINRA reported short interest of 53,681,529 shares in PACB as of the October 30, 2026 settlement, a 14.4% increase from the prior period — about 4.1 days to cover at its recent average daily volume. On November 20, 2026, 60.8% of PACB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)53,681,529 shares as of October 30, 2026
Change vs prior period▲ 14.4%
Days to cover4.14 at avg daily volume of 12,977,933
Daily short volume (FINRA facilities)60.8% of 6,631,949 shares on November 20, 2026
5-day average short volume65.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for PACB, detected from its recent SEC filings · based on capital-structure filings through 2026-11-10.

1 recent capital raiseATM program

New $100M At-The-Market Program · Dilution If Fully Drawn

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with P →
$1.63 +0.28% today
52-week range · as of 2026-11-10 $1.07 – $3.44
Market cap
$510.07M
Volume
13.7M (1.1× avg)
3-mo avg 12.7M
Live data · 2026-11-21 21:15 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PACB - Latest Insights

PACB
Nov 10, 2026, 4:05 PM EST
Filing Type: 424B5
Importance Score:
7
Price at Filing: $2.25
Real-time Price: $1.63 info
Change: -$0.6144 (-27%) info
Market Cap: $510.071M info
PACB
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.54
Real-time Price: $1.63 info
Change: -$0.9054 (-36%) info
Market Cap: $510.071M info
PACB
Nov 04, 2026, 5:41 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.60
Real-time Price: $1.63 info
Change: -$0.9654 (-37%) info
Market Cap: $510.071M info
PACB
Nov 04, 2026, 4:09 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.68
Real-time Price: $1.63 info
Change: -$1.05 (-39%) info
Market Cap: $510.071M info
PACB
Nov 04, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.57
Real-time Price: $1.63 info
Change: -$0.9354 (-36%) info
Market Cap: $510.071M info
PACB
Aug 06, 2026, 5:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.16
Real-time Price: $1.63 info
Change: +$0.4746 (+41%) info
Market Cap: $510.071M info
PACB
Aug 05, 2026, 6:20 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1.27
Real-time Price: $1.63 info
Change: +$0.3646 (+29%) info
Market Cap: $510.071M info
PACB
Aug 05, 2026, 4:42 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.25
Real-time Price: $1.63 info
Change: +$0.3846 (+31%) info
Market Cap: $510.071M info
PACB
Aug 05, 2026, 4:23 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.29
Real-time Price: $1.63 info
Change: +$0.3446 (+27%) info
Market Cap: $510.071M info
PACB
Aug 05, 2026, 9:05 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.44
Real-time Price: $1.63 info
Change: +$0.1946 (+14%) info
Market Cap: $510.071M info
PACB
Jul 09, 2026, 4:43 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $1.63 info
Change: +$0.0246 (+2%) info
Market Cap: $510.071M info
PACB
Jun 05, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.64
Real-time Price: $1.63 info
Change: -$0.0054 (-0.33%) info
Market Cap: $510.071M info
PACB
Jun 04, 2026, 5:19 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.64
Real-time Price: $1.63 info
Change: -$0.0054 (-0.33%) info
Market Cap: $510.071M info
PACB
May 22, 2026, 4:50 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $1.21
Real-time Price: $1.63 info
Change: +$0.4246 (+35%) info
Market Cap: $510.071M info
PACB
May 08, 2026, 5:27 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.44
Real-time Price: $1.63 info
Change: +$0.1952 (+14%) info
Market Cap: $510.071M info
PACB
May 07, 2026, 5:16 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.55
Real-time Price: $1.63 info
Change: +$0.0846 (+5%) info
Market Cap: $510.071M info
PACB
May 07, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.55
Real-time Price: $1.63 info
Change: +$0.0846 (+5%) info
Market Cap: $510.071M info
PACB
Apr 23, 2026, 4:40 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $1.58
Real-time Price: $1.63 info
Change: +$0.0546 (+3%) info
Market Cap: $510.071M info
PACB
Apr 21, 2026, 9:05 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.73
Real-time Price: $1.63 info
Change: -$0.0959 (-6%) info
Market Cap: $510.071M info
PACB
Apr 15, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.62
Real-time Price: $1.63 info
Change: +$0.0146 (+0.90%) info
Market Cap: $510.071M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets